Arizona is currently home to 1791 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02339571
Recruiting
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Kingman Regional Medical Center, Kingman, Arizona
Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Register for Updates
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
NCT01810913
Recruiting
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, wor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Banner University Medical Center - Tucson, Tucson, Arizona
Conditions: Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
Register for Updates
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
NCT00739362
Recruiting
This study will determine whether electrical stimulation of an area of the brain called the dorsolateral prefrontal cortex, which is important in determining the feeling of fullness after eating, affects how much food a person eats and weight loss over 4 weeks. It will also compare weight changes in people who attend weight loss counseling sessions and those who do not over this period of time. Obese, non-diabetic people between 18 and 60 years of age who are in good health and who live in the... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/18/2024
Locations: NIDDK, Phoenix, Phoenix, Arizona
Conditions: Electric Stimulation Therapy, Obesity, Weight Loss, Eating
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
NCT06326060
Recruiting
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2024
Locations: Centricity Research-Arizona, Mesa, Arizona
Conditions: Obesity
Register for Updates
Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
NCT06285214
Recruiting
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Urological Associates of Southern Arizona, Tucson, Arizona
Conditions: Interstitial Cystitis/Bladder Pain Syndrome
Register for Updates
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06230523
Recruiting
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 13 visits.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2024
Locations: The Institute for Liver Health dba Arizona Clinical Trials, Mesa, Arizona
Conditions: Obesity, Overweight and Obesity
Register for Updates
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona
Conditions: Focal Epilepsy
Register for Updates
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199
Recruiting
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/17/2024
Locations: Affiliated Dermatology, Scottsdale, Arizona
Conditions: Plaque Psoriasis
Register for Updates
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
NCT06045221
Recruiting
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Absolute Clinical Research, Phoenix, Arizona
Conditions: Type 2 Diabetes
Register for Updates
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239
Recruiting
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Banner Health MD Anderson AZ, Gilbert, Arizona
Conditions: Metastatic Breast Cancer
Register for Updates
Ph4 PSG Combined JZP258-407
NCT05875974
Recruiting
This study will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic hypersomnia (IH) or narcolepsy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2024
Locations: Perseverance Research Center, LLC, Scottsdale, Arizona
Conditions: Idiopathic Hypersomnia, Narcolepsy
Register for Updates
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective Upadacitinib is in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active UC and is being developed for moderate- to severely active UC in pediatric participa... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
04/17/2024
Locations: Phoenix Children's Hospital /ID# 250135, Phoenix, Arizona
Conditions: Ulcerative Colitis
Register for Updates